Scarica l'app Stockscreener
14.01
0.14%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Myotonic Dystrophy Pipeline Analysis 2024: FDA Approvals - openPR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc.(DYN) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc.(DYN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Dyne therapeutics SVP Richard Scalzo sells $34,707 in stock By Investing.com - Investing.com Nigeria
Dyne therapeutics SVP Richard Scalzo sells $34,707 in stock - Investing.com India
Dyne Therapeutics Officer Sells Shares to Satisfy Tax Obligations - TradingView
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
(DYN) Technical Data - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Sets New 52-Week LowWhat's Next? - MarketBeat
abrdn plc Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics to Present Key Data from DELIVER and ACHIEVE Clinical Trials at 2025 MDA Conference - Nasdaq
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific - The Bakersfield Californian
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference - GlobeNewswire
Major Clinical Data Alert: Dyne's DMD and DM1 Trial Results Set for Exclusive MDA Conference Reveal - StockTitan
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) - Yahoo Finance
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 5%Here's What Happened - MarketBeat
abrdn plc Purchases New Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics To Present At Oppenheimer Healthcare Conference; Webcast At 4:00 PM ET - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Dyne Therapeutics (NASDAQ:DYN) Trading Up 7%Time to Buy? - MarketBeat
Dyne Therapeutics Shares Rise Premarket as DMD Study Gets FDA Nod -July 05, 2022 at 08:18 am EDT - Marketscreener.com
Jennison Associates LLC Sells 135,037 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now - Insider Monkey
DYN Stock Sees Surge of Approximately 15.81% in Last Five Days - Knox Daily
Learn to Evaluate (DYN) using the Charts - Stock Traders Daily
10 Best Rebound Stocks To Invest In Now - Insider Monkey
Investor’s Delight: Dyne Therapeutics Inc (DYN) Closes Weak at 13.87, Down -2.46 - The Dwinnex
Dyne Therapeutics Inc’s results are impressive - US Post News
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
DYN (Dyne Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Dyne Therapeutics Reveals Latest Developments at Major Healthcare ConferenceKey Updates Coming - StockTitan
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era - Yahoo Finance
Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Recent Analysts’ Ratings Changes for Dyne Therapeutics (DYN) - Defense World
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround - MSN
Dyne Therapeutics (NASDAQ:DYN) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Guggenheim - Defense World
Dyne Therapeutics' (DYN) Buy Rating Reiterated at Guggenheim - MarketBeat
(DYN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week LowTime to Sell? - MarketBeat
Dyne Therapeutics: Moving Forward On 2 Key Fronts - Seeking Alpha
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):